title: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy.
abstract: OBJECTIVE
  To review the state of the art of laboratory monitoring of oral anticoagulant therapy, as reflected by the medical literature and the consensus opinion of recognized experts in the field, and to make recommendations for improvement in laboratory monitoring of oral anticoagulant therapy.
  
  
  METHODS
  Review of the medical literature, primarily from the last 10 years, and current laboratory practices by a panel of 8 international experts in the field of oral anticoagulant monitoring.
  
  
  METHODS
  After an initial assessment of the literature, key points were identified. Experts were assigned to do an in-depth review of the literature and current practices relevant to each of the key points and to prepare a summary of their findings and recommendations. A draft manuscript was prepared and circulated to every participant in the College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy prior to the conference. Each of the key points and associated recommendations was then presented for discussion at the Conference. Recommendations were accepted if a consensus of the 26 experts attending the Conference was reached. The results of the discussion were used to revise the manuscript into its final form.
  
  
  CONCLUSIONS
  Consensus was reached on 12 recommendations concerning the laboratory monitoring of oral anticoagulant therapy. Detailed discussion of the rationale for each of these recommendations is found in the text of this article. Discussion of points on which consensus was not reached is also included in the text. It is hoped that widespread adoption of these recommendations will further improve the laboratory monitoring of oral anticoagulant therapy.
authors.affiliation: Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Fairweather
authors.forename: J
authors.initials: J
authors.lastname: Ansell
authors.forename: A M
authors.initials: AM
authors.lastname: van den Besselaar
authors.forename: J T
authors.initials: JT
authors.lastname: Brandt
authors.forename: H I
authors.initials: HI
authors.lastname: Bussey
authors.forename: L
authors.initials: L
authors.lastname: Poller
authors.forename: D A
authors.initials: DA
authors.lastname: Triplett
authors.forename: R H
authors.initials: RH
authors.lastname: White
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D001780:Blood Coagulation Tests / Q000379:methods* / Q000592:standards / Q000639:trends; D002138:Calibration; D016903:Drug Monitoring / Q000379:methods / Q000639:trends; D006333:Heart Failure / Q000097:blood; D006493:Heparin / Q000097:blood; D006801:Humans; D008107:Liver Diseases / Q000097:blood; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D010338:Pathology, Clinical / Q000379:methods* / Q000592:standards / Q000639:trends; D019095:Point-of-Care Systems; D012016:Reference Values; D012648:Self Care; D012680:Sensitivity and Specificity; D013925:Thromboplastin / Q000592:standards; D014481:United States
chemical_list: D000925:Anticoagulants; D016682:Lupus Coagulation Inhibitor; D006493:Heparin; D013925:Thromboplastin